Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Company reported that on October 5, 2022, the Company purchased 10,500 shares of common stock at $7.0679 per share.
The Company reported that on October 4, 2022, the Company purchased 38,035 shares of common stock at $6.99 per share. Anthony Hayes, CEO of AIkido stated, "We believe the Company stock continues to be undervalued and we are using this opportunity to enhance shareholder value by reducing the amount of stock that is outstanding."
Shalom Auerbach board member on AMRR doesn’t mess around.
Shalom Auerbach, a significant stockholder of AIkido Pharma Inc. (NASDAQ: AIKI) beneficially owning approximately 3.4% of its common stock, today issued the following letter to members of the AIkido Pharma Inc. Board of Directors:
https://www.streetinsider.com/dr/news.php?id=20187179&gfv=1
AIkido Pharma announces $3M share repurchase program
https://ih.advfn.com/stock-market/NASDAQ/alkido-pharma-AIKI/stock-news/87087386/aikido-pharma-announces-3m-share-repurchase-progr
Classic dog pile here. I'm out and won't be back.
AIKI .47 - So, outsiders have sold this company's stock down to less than .50-on-the-dollar and insiders aren't filing Form-4-Buys by the truckload? How can management EVER promote it's own stock again when they show no interest in less than .50-on-the-dollar?
And what would be management's risk be in buying here at less than .50-on-the-dollar? It goes down to .25-on-the-dollar...whoa-is-me
One of the worst companies I've invested in. Finally dumped it for big loss. I obviously played the fool again. Glta
AIKI...73...Bullish 3 Gap Downs Reversal Pattern to the Upside on this Oversold Chart...
Psar flipped Bullish...Been accumulating under $1...
Chart https://schrts.co/exhPMSRA ...
Looks like good news AlKl
https://apple.news/AnumIdrGsR-CRYxMFTxj-5Q
This should go over a dollar soon here!!!!
AIkido owns 525,000 shares of DatChat, which it previously purchased for $500,000.00. As of September 13th, DatChat shares closed at $6.54, well higher than its IPO price and representing a more than 600% return or an additional $3,433,500.00 added to AIKI balance sheet. $AIKI
AIkido owns 525,000 shares of DatChat, which it previously purchased for $500,000.00. As of September 13th, DatChat shares closed at $6.54, well higher than its IPO price and representing a more than 600% return or an additional $3,433,500.00 added to AIKI balance sheet. $AIKI
— Tommy Coops (@ohheytommy) October 12, 2021
AIKI...92...on the P/M Gappa...:partying_face:
Impressed with the CEO management taking investment stakes in pivotal companies, thereby adding significant value here. Great job IMO.
Interesting, low ss here...
Very volatile but looks ready
Would be nice... it has been ages since they did the financing around $1.65 and it began to drop ever since
AIkido Pharma Releases Shareholder Update; Near Term Catalysts Approaching
AIKI...86...Tue, July 27, 2021, 10:00 AM
AIkido's License to Technology Includes Targeted Psilocybin Treatment for Cancer Patients
NEW YORK, July 27, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for application No.: 16/477,125. This technology relates to the use of novel and proprietary central nervous system (CNS) homing peptides. This technology has been exclusively sublicensed to AIkido Pharma for use of psilocybin for the therapeutic treatment of neuroinflammatory disease in cancer patients.
AIKI...97...Bounce off the .85 range on the Bullish Engulfing Reversal Candle to the Upside...
Psar flipped to a Bullish Buy Position...as the MACD Crossed to the positive side...
Chart...https://schrts.co/FqVVQIHY ...
No respect from the street on this company. Corporate..how about getting some dignity and respect by actually executing and aggressive communications to the investing arena? Grow a pair..
Yeah definitely under substantial book value here. Not just on cash, but potential pipeline, nols, licensing rev's. You buy the dips here and wait on a significant return.
BULLISH RESEARCH ARTICLE! Trading under cash and great upside on great results. https://insiderfinancial.com/akido-pharmas-aiki-clinical-trial-results-continues-to-validates-gileads-21-billion-purchase-of-immunomedics/181580/
* * $AIKI Video Chart 04-21-2021 * *
Link to Video - click here to watch the technical chart video
AIKI...86...NEW YORK, April 16, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today noted that a recent study announced positive early results from a PSMA 617-Lu177 study conducted by a leading global pharmaceutical company. The report provides strong indications for analogous success in similar technology the Company is helping to develop.
The article can be accessed at:
https://www.thepharmaletter.com/article/further-vindication-for-novartis-in-radioligand-space
AIKI...$1.20...in the P/M...NEW YORK, April 7, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it has been granted an exclusive sublicense to technology related to the use of novel and proprietary central nervous system (CNS) homing peptides for the therapeutic treatment of neuroinflammatory disease in cancer patients...
https://www.otcmarkets.com/stock/AIKI/news/story?e&id=1857821
AIKI...$1.17...Bidding the Lower Band to the 20ma to add to my Core Position...
Looking for the 2 Open Gaps to fill and a $2 Breakout..imo...we shall see....
Chart...https://schrts.co/BrjKBXYy ...
AIKI...$1.17...in the P/M...https://www.otcmarkets.com/stock/AIKI/news/story?e&id=1849940 ...:party:
$aiki $1.17 ? 0.0 (0.00%)
Volume: 3,920,435 @03/26/21 7:41:58 PM EDT
* * $AIKI Video Chart 03-24-2021 * *
Link to Video - click here to watch the technical chart video
* * $AIKI Video Chart 03-15-2021 * *
Link to Video - click here to watch the technical chart video
Today should be good for AIKI
Come on AIKI- for pete's sake!
News out yesterday. Closed up. AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)
https://finance.yahoo.com/news/aikido-pharma-inc-present-h-140000406.html
$aiki $1.19 v -0.04 (-3.25%)
Volume: 13,189,558 @02/26/21 7:59:56 PM EST
AIKI mentioned in this Magic Mushroom article https://insiderfinancial.com/eight-mushroom-penny-stocks-causing-portfolios-to-go-psychedelic/181054/
On January 12, 2021, AIkido Pharma Inc., a Delaware corporation (the “Company”), reconvened its 2020 annual meeting of stockholders (the “Meeting”). At the Meeting, the Company’s did not obtain the approval from stockholders that held a majority of the issued and outstanding shares of common stock as of the record date that was set for determination of stockholders entitled to notice and to vote at the Meeting of the proposal to amend the Company’s amended and restated certificate of incorporation (the “Amended and Restated Certificate of Incorporation”) to effect a reverse stock split of the Company’s common stock to a ratio of up to one-for-ten.
https://ih.advfn.com/stock-market/NASDAQ/alkido-pharma-AIKI/stock-news/84124954/current-report-filing-8-k
I think the big boys are here now.
47mm shares from the offering. Be about 80mm now but yeah they shouldn't need to RS from here. I think that was more relevant for Nasdaq when they were well below $1.00. $AIKI
Followers
|
156
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8287
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators |
Kucera Paper Lipid Nucleoside Conjugates for the Treatment of Cancer
Kucers & Pardee Paper Improving Nucleoside Analogs via Lipid Conjugation
The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for Leukemia
Short-term Toxicity Study of DHA-dFdC
AIkido Pharma Inc. seeks to enhance shareholder value not only through exceptional business performance and practices,
but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual
and institutional investor includes stock price and history, upcoming events and presentations and financial documents.
AIkido Pharma Inc. is traded on the Nasdaq under the ticker symbol AIKI.
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.
The Spherix platform contains patented technology from leading universities and researchers and we seek to develop
our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University.
Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models.
The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs.
Our AML drug is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care.
In addition, we are constantly seeking to grow our pipe to treat unmet medical needs in oncology.
https://ir.aikidopharma.com/stock-information/
$AIKI Spherix Incorporated, a biotechnology company,focuses on developing small-molecule anti-cancer therapeutics.
Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
The company's platform consists of patented technology from leading universities and researchers and in the process of developing an
innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at
Austin and Wake Forest University.
It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic
markers in people that indicate an increased risk of developing pancreatic cancer.
Spherix Incorporated was founded in 1967 and is based in New York, New York.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |